Share

    


In This Section

Home / Blurb / Discussion Detail

FDA Approves Pembrolizumab for Hepatocellular Carcinoma

On November 9, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc.) for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Read the Merck press release here.

Posted 11/12/2018